new a vaccine that targets inflamed brain cells associated with Alzheimer’s disease may be key to preventing or reversing the course of the disease, according to preliminary research presented at the 2023 Basic Cardiovascular Science Scientific Sessions American Heart Association.
The vaccine that called SAGP-SEN1, it is designed to kill cells senescent cells expressing aging-associated glycoprotein (SAGP). Senescent cells are cells that have grown old and become harmful to the body. They are known to be involved in the development of various diseases, including Alzheimer’s disease.
New SAGP-SEN1 vaccine in study given to mice with Alzheimer’s disease. Vaccine-treated mice showed significant improvements in memory and learning compared to non-vaccinated mice. They also showed a decrease in amyloid plaques and neurofibrillary tangles, which are the two main markers of this condition.
Main author studyTse-Lun Xiao, explained that “Alzheimer’s disease accounts for 50% to 70% of patients with dementia worldwide. A new vaccine test from our study in mice points to a potential way to prevent or reverse the disease. The future challenge will be to achieve similar results in humans.”
Researchers believe that this immunization could be a new hope for patients with Alzheimer’s disease. However, more research is needed to determine if the vaccine is safe and effective in humans..